Timothy Leroux

Timothy Leroux

Auto-generated profile, based on publicly available information

Timothy Leroux

The Arthritis Program, University Health Network, Toronto, Canada

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Journal of Shoulder and Elbow Surgery
Verified
Journal Article
Closed access
ELEva Y. Liu
Eva Y. Liu
DKDorsa Kord
Dorsa Kord
NHNolan S. Horner
Nolan S. Horner
TLTimothy Leroux
Timothy Leroux
BABashar Alolabi
Bashar Alolabi
MKMoin Khan
Moin Khan

1 July 2020 in Journal of Shoulder and Elbow Surgery
Verified
Journal Article
Closed access
JCJulien Clouette
Julien Clouette
TLTimothy Leroux
Timothy Leroux
ASAjaykumar Shanmugaraj
Ajaykumar Shanmugaraj
MKMoin Khan
Moin Khan
CGChetan Gohal
Chetan Gohal
RPRyan A. Paul
Ryan A. Paul

5 February 2020 in Sports Health: A Multidisciplinary Approach
Verified
Journal Article
Closed access
PDF file
SDShgufta Docter
Shgufta Docter
MKMoin Khan
Moin Khan
CGChetan Gohal
Chetan Gohal
BRBheeshma Ravi
Bheeshma Ravi
MBMohit Bhandari
Mohit Bhandari
TLTimothy Leroux
Timothy Leroux
Context: Cannabis use has increased, in large part due to decriminalization. Despite this increase in usage, it remains unclear what proportion of athletes use cannabis and what effect it has on athletic performance and recovery. Objective: To systematically review cannabis use among athletes, including epidemiology, effect on performance and recovery, and regulations for use in sport. Data Sources: PubMed, MEDLINE, and EMBASE databases were queried from database inception through November 15, 2018. A hand search of policies, official documents, and media reports was performed for relevant information. Study Selection: All studies related to cannabis use in athletes, including impact on athletic performance or recovery, were included. Study Design: Systematic review. Level of Evidence: Level 4. Data Extraction: Demographic and descriptive data of included studies relating to epidemiology of cannabis use in athletes were extracted and presented in weighted means or percentages where applicable. Results: Overall, 37 studies were included, of which the majority were cross-sectional studies of elite and university athletes. Among 11 studies reporting use among athletes (n = 46,202), approximately 23.4% of respondents reported using cannabis in the past 12 months. Two studies found a negative impact on performance, while another 2 studies found no impact. There was no literature on the influence of cannabis on athletic recovery. Across athletic organizations and leagues, there is considerable variability in acceptable thresholds for urine tetrahydrocannabinol levels (>15 to 150 ng/mL) and penalties for athletes found to be above these accepted thresholds. Conclusion: Overall, these results suggest that approximately 1 in 4 athletes report using cannabis within the past year. Based on the available evidence, cannabis does not appear to positively affect performance, but the literature surrounding this is generally poor. Given the variability in regulation across different sport types and competition levels, as well as the growing number of states legalizing recreational cannabis use, there is a need to improve our understanding of the effects of cannabis use on the athlete and perhaps adopt a clearer and overarching policy for the use of cannabis by athletes in all sports and at all levels.

1 November 2019 in Arthroscopy
Verified
Journal Article
Closed access
SDShgufta Docter
Shgufta Docter
MKMoin Khan
Moin Khan
SESeper Ekhtiari
Seper Ekhtiari
CVChristian Veillette
Christian Veillette
RPRyan Paul
Ryan Paul
TLTimothy Leroux
Timothy Leroux

7 August 2018 in JBJS Open Access
Verified
Journal Article
Open access
RFRachel M. Frank
Rachel M. Frank
SLSimon Lee
Simon Lee
SSShelby Sumner
Shelby Sumner
JGJustin Griffin
Justin Griffin
TLTimothy Leroux
Timothy Leroux
ARAnthony A. Romeo
Anthony A. Romeo
Background: The purpose of this retrospective study was to compare outcomes and complications in patients with and patients without a history of non-arthroplasty surgery on the ipsilateral shoulder who later underwent total shoulder arthroplasty (TSA) or reverse total shoulder arthroplasty (RTSA). We hypothesized that patients who had undergone prior surgery would have more complications and worse clinical outcomes. Methods: Consecutive patients who had undergone shoulder arthroplasty and had been followed for a minimum of 2 years were evaluated with the American Shoulder and Elbow Society scoring system (ASES), Simple Shoulder Test (SST), and Visual Analog Scale (VAS) assessments and with physical examination, including range-of motion assessments. Complications and outcomes in patients who had undergone prior surgery on the ipsilateral shoulder (PS group) were compared with those in patients without such a history (NPS group). Results: Data on 506 shoulder arthroplasties (263 TSA and 243 RTSA) were available for analysis. A total of 144 patients (28%) had an average of 1.9 ± 1.0 surgical procedures on the ipsilateral shoulder before arthroplasty. The average age in the PS group was significantly younger at the time of arthroplasty compared with the NPS group (61.6 ± 10.2 years compared with 68.2 ± 8.6 years, p = 0.035). At an average follow-up of 42.8 ± 16.4 months, both groups had significant improvements in ASES, SST, VAS, and range-of-motion values (p < 0.05 for all). All outcome scores in the PS group were significantly lower than those in the NPS group (p < 0.001 for all). The PS group also had a significantly higher complication rate than the NPS group (19.4% compared with 4.4%, p < 0.001), and multivariate regression analysis revealed that prior surgery was a significant independent predictor of postoperative complications. There were no differences between the PS and NPS groups in the number of postoperative infections (p = 0.679), reoperations (p = 0.553), or transfusions (p = 0.220). Conclusions: Patients who have a history of prior surgery on the ipsilateral shoulder derive benefit from shoulder arthroplasty, but their magnitude of improvement and final scores are lower than those of patients who do not have such a history. This information can be used to counsel this challenging patient population on expected outcomes following shoulder arthroplasty. Level of Evidence: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.

1 October 2020 in The Journal of Arthroplasty
Verified
Journal Article
Closed access
NMNaomi Maldonado-Rodriguez
Naomi Maldonado-Rodriguez
SESeper Ekhtiari
Seper Ekhtiari
MKMoin M. Khan
Moin M. Khan
BRBheeshma Ravi
Bheeshma Ravi
RGRajiv Gandhi
Rajiv Gandhi
TLTimothy Leroux
Timothy Leroux